

Richard Conway

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396380/publications.pdf>

Version: 2024-02-01

162
papers

3,293
citations

201674

27
h-index

175258

52
g-index

163
all docs

163
docs citations

163
times ranked

3738
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
2	Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. <i>Arthritis and Rheumatology</i> , 2014, 66, 803-812.	5.6	178
3	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
4	JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 519-531.	3.5	124
5	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
6	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	5.6	117
7	Risk of liver disease in methotrexate treated patients. <i>World Journal of Hepatology</i> , 2017, 9, 1092.	2.0	111
8	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	8.0	105
9	Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. <i>BMJ</i> , 2015, 350, h1269-h1269.	6.0	98
10	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
11	Ustekinumab for the treatment of refractory giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1578-1579.	0.9	87
12	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
13	Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment. <i>Frontiers in Medicine</i> , 2019, 6, 238.	2.6	73
14	Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 156-162.	3.4	72
15	Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 523-528.	3.4	69
16	MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. <i>Journal of Autoimmunity</i> , 2017, 79, 105-111.	6.5	66
17	Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 15.	2.4	65
18	Long-term outcome of an AMAU—a decade's experience. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 43-49.	0.5	64

#	ARTICLE	IF	CITATIONS
19	Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. <i>Rheumatology</i> , 2019, 58, 1900-1906.	1.9	62
20	Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2016, 43, 855-860.	2.0	59
21	Increased Body Mass Index in Ankylosing Spondylitis Is Associated with Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise. <i>Journal of Rheumatology</i> , 2012, 39, 2310-2314.	2.0	57
22	Serum potassium levels as an outcome determinant in acute medical admissions. <i>Clinical Medicine</i> , 2015, 15, 239-243.	1.9	49
23	Deprivation as an outcome determinant in emergency medical admissions. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 245-251.	0.5	41
24	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	1.9	40
25	Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1815-1824.	0.9	38
26	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
27	Radiology imaging delays as independent predictors of length of hospital stay for emergency medical admissions. <i>Clinical Radiology</i> , 2016, 71, 912-918.	1.1	30
28	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
29	High-sensitivity troponin as an outcome predictor in acute medical admissions. <i>Postgraduate Medical Journal</i> , 2014, 90, 311-316.	1.8	25
30	Safety of joint and soft tissue injections in patients on warfarin anticoagulation. <i>Clinical Rheumatology</i> , 2013, 32, 1811-1814.	2.2	24
31	Social deprivation and hospital admission rates, length of stay and readmissions in emergency medical admissions. <i>European Journal of Internal Medicine</i> , 2015, 26, 766-771.	2.2	24
32	Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 29-35.	1.6	23
33	Methotrexate and lung disease in rheumatoid arthritis. <i>Panminerva Medica</i> , 2017, 59, 33-46.	0.8	23
34	Calcium-Containing Crystals and Osteoarthritis: an Unhealthy Alliance. <i>Current Rheumatology Reports</i> , 2018, 20, 13.	4.7	22
35	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	2.0	22
36	Comparative influence of Acute Illness Severity and comorbidity on mortality. <i>European Journal of Internal Medicine</i> , 2020, 72, 42-46.	2.2	21

#	ARTICLE	IF	CITATIONS
37	Does admission via an Acute Medical Unit influence hospital mortality? 12 years' experience in a large Dublin Hospital. <i>Acute Medicine</i> , 2014, 13, 152-158.	0.3	21
38	Diagnostic Utility of Computed Tomographic Angiography in Giant-Cell Arteritis. <i>Stroke</i> , 2018, 49, 2233-2236.	2.0	19
39	Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , 2021, 232, 49-59.	5.0	19
40	Consultant volume, as an outcome determinant, in emergency medical admissions. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 831-837.	0.5	18
41	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	3.9	18
42	Deprivation influences the emergency admission rate of ambulatory care sensitive conditions. <i>Clinical Medicine</i> , 2016, 16, 119-123.	1.9	17
43	Does admission via an acute medical unit influence hospital mortality? 12 years' experience in a large Dublin hospital. <i>Acute Medicine</i> , 2014, 13, 152-8.	0.3	17
44	Deprivation index and dependency ratio are key determinants of emergency medical admission rates. <i>European Journal of Internal Medicine</i> , 2015, 26, 709-713.	2.2	15
45	Fifteen-year outcomes of an acute medical admission unit. <i>Irish Journal of Medical Science</i> , 2018, 187, 1097-1105.	1.5	15
46	A case of Behcet's syndrome presenting as focal myositis. <i>Rheumatology</i> , 2012, 51, 975-975.	1.9	13
47	The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 1823-1827.	2.2	13
48	Emergency readmissions are substantially determined by acute illness severity and chronic debilitating illness: A single centre cohort study. <i>European Journal of Internal Medicine</i> , 2015, 26, 12-17.	2.2	13
49	Patient risk profiling in acute medicine: the way forward?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 689-696.	0.5	13
50	Outcomes in acute medicine - Evidence from extended observations on readmissions, hospital length of stay and mortality outcomes. <i>European Journal of Internal Medicine</i> , 2019, 66, 69-74.	2.2	13
51	Use of Adalimumab in Treatment of Autoimmune Sensorineural Hearing Loss: A Word of Caution. <i>Journal of Rheumatology</i> , 2011, 38, 176.1-176.	2.0	12
52	Hyponatraemia during an emergency medical admission as a marker of illness severity & case complexity. <i>European Journal of Internal Medicine</i> , 2019, 59, 60-64.	2.2	12
53	Juvenile Versus Adult-Onset Ankylosing Spondylitis: Are We Comparing Apples and Oranges?. <i>Journal of Rheumatology</i> , 2012, 39, 887-889.	2.0	11
54	Adherence to uric acid treatment guidelines in a rheumatology clinic. <i>Clinical Rheumatology</i> , 2012, 31, 1707-1711.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Consultant experience as a determinant of outcomes in emergency medical admissions. European Journal of Internal Medicine, 2014, 25, 151-155.	2.2	10
56	Influence of social deprivation, overcrowding and family structure on emergency medical admission rates. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 675-680.	0.5	10
57	Social deprivation, population dependency ratio and an extended hospital episode â€” Insights from acute medicine. European Journal of Internal Medicine, 2015, 26, 714-719.	2.2	9
58	Targets and the emergency medical system â€” intended and unintended consequences. European Journal of Emergency Medicine, 2015, 22, 235-240.	1.1	9
59	Time patterns in mortality after an emergency medical admission; relationship to weekday or weekend admission. European Journal of Internal Medicine, 2016, 36, 44-49.	2.2	9
60	Predicting Outcomes in Emergency Medical Admissions Using a Laboratory Only Nomogram. Computational and Mathematical Methods in Medicine, 2017, 2017, 1-8.	1.3	9
61	Current advances in the treatment of giant cell arteritis: the role of biologics. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1982722.	2.7	9
62	Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey. Rheumatology Advances in Practice, 0, , .	0.7	9
63	Hyponatraemia in Emergency Medical Admissionsâ€”Outcomes and Costs. Journal of Clinical Medicine, 2014, 3, 1220-1233.	2.4	8
64	Increased platelet reactivity as measured by plasma glycoprotein VI in gout. Platelets, 2018, 29, 821-826.	2.3	8
65	Allopurinol and Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, 1687-1692.	27.0	8
66	Prognostic Value Of Blood Cultures as an Illness Severity Marker In Emergency Medical Admissions. Acute Medicine, 2020, 19, 83-89.	0.3	8
67	Medical Record Documentation Among Interns: A Prospective Quality Improvement Study. Irish Medical Journal, 2015, 108, 183-5.	0.0	8
68	Improved outcomes of high-risk emergency medical admissions cared for by experienced physicians. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 119-125.	0.5	7
69	Social deprivation and the rate of emergency medical admission for older persons. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 645-651.	0.5	7
70	Improved mortality outcomes over time for weekend emergency medical admissions. Irish Journal of Medical Science, 2018, 187, 5-11.	1.5	7
71	Treating interstitial lung disease in rheumatoid arthritis â€” the embers of hope. Rheumatology, 2020, 59, 3589-3590.	1.9	7
72	Correspondence to: â€”Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryâ€™ by Gianfrancesco <i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e140-e140.	0.9	7

#	ARTICLE	IF	CITATIONS
73	Vision-related and health-related quality of life in patients with giant cell arteritis. European Journal of Ophthalmology, 2021, 31, 727-733.	1.3	7
74	Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. Rheumatology Advances in Practice, 2021, 5, rkab031.	0.7	7
75	POS1162â€¦PREDICTORS OF HOSPITALISATION IN PATIENTS WITH RHEUMATIC DISEASE AND COVID-19 IN IRELAND: DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 859-860.	0.9	7
76	Biologic Therapies for Giant Cell Arteritis. Biologics: Targets and Therapy, 2021, Volume 15, 17-29.	3.2	7
77	The impact of COVID-19 on rheumatology trainingâ€™results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.7	7
78	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. Rheumatology, 2022, 61, SI151-SI156.	1.9	7
79	Benchmarking tocilizumab use for giant cell arteritis. Rheumatology Advances in Practice, 2022, 6, .	0.7	7
80	Factors predicting the hospital episode costs of emergency medical admissions. European Journal of Internal Medicine, 2014, 25, 633-638.	2.2	6
81	Survival analysis of weekend emergency medical admissions. QJM - Monthly Journal of the Association of Physicians, 2017, 110, hcw219.	0.5	6
82	Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab. Clinical Medicine, 2017, 17, 280-281.	1.9	6
83	Is methotrexate contra-indicated in lung involvement of rheumatoid arthritis?. Joint Bone Spine, 2020, 87, 535-537.	1.6	6
84	Rapid Adoption of Telemedicine in Rheumatology Care During the <scp>COVID</scp>â€™19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. ACR Open Rheumatology, 2022, 4, 128-133.	2.1	6
85	Renal Infarction Due to Spontaneous Renal Artery Dissection in Ehlers-Danlos Syndrome Type IV. Journal of Rheumatology, 2012, 39, 199-200.	2.0	5
86	Effect of social deprivation on the admission rate and outcomes of adult respiratory emergency admissions. Respiratory Medicine, 2017, 125, 94-101.	2.9	5
87	Is there excessive troponin testing in clinical practice? Evidence from emergency medical admissions. European Journal of Internal Medicine, 2021, 86, 48-53.	2.2	5
88	Performance characteristics and predictors of temporal artery ultrasound for the diagnosis of giant cell arteritis in routine clinical practice in a prospective cohort. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 72-78.	0.8	5
89	High Risk Subgroups Sensitive to Air Pollution Levels Following an Emergency Medical Admission. Toxics, 2017, 5, 27.	3.7	4
90	Persons with disability, social deprivation and an emergency medical admission. Irish Journal of Medical Science, 2018, 187, 593-600.	1.5	4

#	ARTICLE	IF	CITATIONS
91	Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?. Expert Opinion on Investigational Drugs, 2022, 31, 921-932.	4.1	4
92	Mortality outcomes and emergency department wait times – the paradox in the capacity limited system. Acute Medicine, 2018, 17, 130-136.	0.3	4
93	Expanding access to rheumatology care: the rheumatology general practice toolbox. Irish Medical Journal, 2015, 108, 48-50.	0.0	4
94	Assessment of service delays and impact on bed utilisation in a major teaching hospital. Irish Journal of Medical Science, 2011, 180, 533-535.	1.5	3
95	A Case of SAPHO Syndrome Presenting as Isolated Iliitis and Spondylitis. Journal of Rheumatology, 2011, 38, 1810-1811.	2.0	3
96	Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology, 2011, 50, 631-632.	1.9	3
97	Tibial Insufficiency Fractures in Rheumatoid Arthritis: A New Clinical Sign: Figure 1.. Journal of Rheumatology, 2012, 39, 1893-1894.	2.0	3
98	Consultant duration of clinical practice as a cost determinant of an emergency medical admission. European Journal of Health Economics, 2015, 16, 561-567.	2.8	3
99	Age and the economics of an emergency medical admission – what factors determine costs?. QJM - Monthly Journal of the Association of Physicians, 2016, 110, hcw161.	0.5	3
100	High prevalence of abnormalities on chest radiography in rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 3375-3380.	2.2	3
101	Correspondence on “Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries”™. Annals of the Rheumatic Diseases, 2021, 80, e170-e170.	0.9	3
102	Non-Specific Clinical Presentations are Not Prognostic and do not Anticipate Hospital Length of Stay or Resource Utilization. European Journal of Internal Medicine, 2021, 87, 75-82.	2.2	3
103	Emergency medical admissions and COVID-19: impact on 30-day mortality and hospital length of stay. Irish Journal of Medical Science, 2021, , 1.	1.5	3
104	Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study. Rheumatology International, 2021, 41, 2133-2146.	3.0	3
105	The Relationship Between Social Deprivation and a Weekend Emergency Medical Admission. Acute Medicine, 2016, 15, 124-129.	0.3	3
106	The Relationship Between Social Deprivation and a Weekend Emergency Medical Admission. Acute Medicine, 2016, 15, 124-129.	0.3	3
107	Prognostic Value Of Blood Cultures as an Illness Severity Marker In Emergency Medical Admissions. Acute Medicine, 2020, 19, 83-89.	0.3	3
108	Anti-Ro 52 positive dermatomyositis presenting as rapidly progressive interstitial lung disease. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 593-594.	0.5	2

#	ARTICLE	IF	CITATIONS
109	Severe respiratory failure due to embolization of cyanoacrylate sclerosant. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 831-832.	0.5	2
110	Air Quality and Hospital Outcomes in Emergency Medical Admissions with Respiratory Disease. Toxics, 2016, 4, 15.	3.7	2
111	The dynamics of the emergency medical readmission – The underlying fundamentals. European Journal of Internal Medicine, 2017, 45, 78-83.	2.2	2
112	Peroneal neuropathy in giant cell arteritis. Rheumatology, 2017, 56, 169-170.	1.9	2
113	Social Factors Determine the Emergency Medical Admission Workload. Journal of Clinical Medicine, 2017, 6, 59.	2.4	2
114	Air pollution and comorbidity burden influencing acute hospital mortality outcomes in a large academic teaching hospital in Dublin, Ireland: a semi-ecologic analysis. Public Health, 2020, 186, 164-169.	2.9	2
115	Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et al. Arthritis Care and Research, 2021, 73, 1056-1057.	3.4	2
116	Acute hepatitis E in an immunocompromised patient with seropositive rheumatoid arthritis on rituximab and long-term methotrexate. Modern Rheumatology Case Reports, 2021, 5, 226-228.	0.7	2
117	Dr. Conway et al reply. Journal of Rheumatology, 2021, , jrheum.210913.	2.0	2
118	An unusual cause of methaemoglobinaemia. Irish Medical Journal, 2009, 102, 184.	0.0	2
119	Relationship of the clinical acuity & complexity to the outcome of an emergency medical admission. Acute Medicine, 2018, 17, 18-25.	0.3	2
120	The Real World of Gout. Journal of Rheumatology, 2013, 40, 755-757.	2.0	1
121	Reply. Arthritis and Rheumatology, 2014, 66, 2642-2642.	5.6	1
122	Broadband access, housing and car ownership as deprivation predictors of the emergency medical admission. European Journal of Internal Medicine, 2016, 35, e25-e26.	2.2	1
123	THU0120 – Long Term Safety and Efficacy of Biosimilar Infliximab among Patients with Inflammatory Arthritis Switched from Reference Product: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 223.2-223.	0.9	1
124	Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson et al. Annals of the Rheumatic Diseases, 2018, 77, e7-e7.	0.9	1
125	Lung function and outcomes in emergency medical admissions. European Journal of Internal Medicine, 2019, 59, 34-38.	2.2	1
126	Glucosamine and mortality: a note of caution. Annals of the Rheumatic Diseases, 2022, 81, e180-e180.	0.9	1

#	ARTICLE	IF	CITATIONS
127	Socio-economic status and the clinical acuity of emergency medical admissions. Panminerva Medica, 2018, 60, 235-237.	0.8	1
128	Image of the month: Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE): An important spot diagnosis. Clinical Medicine, 2020, 20, 524-524.	1.9	1
129	Methotrexate and The Lung in Rheumatoid Arthritis. European Medical Journal Rheumatology, 0, , 80-90.	0.0	1
130	Reply to: methotrexate and not much harm to the lungs by H. Yazici. Clinical and Experimental Rheumatology, 2014, 32, S-11.	0.8	1
131	Pseudo pseudogout. Irish Medical Journal, 2014, 107, 333-4.	0.0	1
132	Mortality outcomes and emergency department wait times - the paradox in the capacity limited sytem. Acute Medicine, 2018, 17, 130-136.	0.3	1
133	THU0428â€¦Methotrexate Use is not Associated with an Increased Risk of Lung Disease: A Meta-Analysis of Randomised Controlled Trials: Table 1.. Annals of the Rheumatic Diseases, 2014, 73, 330.2-330.	0.9	0
134	THU0139â€¦Methotrexate Use and Liver Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials. Annals of the Rheumatic Diseases, 2014, 73, 227.1-227.	0.9	0
135	019AGE AND THE ECONOMICS OF AN EMERGENCY MEDICAL ADMISSION - WHAT FACTORS DETERMINE COST?. Age and Ageing, 2016, 45, ii13.168-ii56.	1.6	0
136	Response to: â€œBiologic agents for giant cell arteritis: treat to targetâ€™ by Moiseev <i>et al</i>. Annals of the Rheumatic Diseases, 2016, 75, e59-e59.	0.9	0
137	THU0312â€¦Performance characteristics and predictors of temporal artery ultrasound and biopsy for the diagnosis of giant cell arteritis in a real world population; a prospective cohort study. , 2017, , .		0
138	Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis. Annals of the Rheumatic Diseases, 2018, 77, 1695-1697.	0.9	0
139	Rising Emergency Admission and Readmission Ratesâ€”a Retrospective Study of Demographic and Socio-economic Factors. Journal of General Internal Medicine, 2018, 33, 1623-1625.	2.6	0
140	Admission and readmission rate incidences from deprived areasâ€”impact of a classical or multi-dimensional model. Irish Journal of Medical Science, 2019, 188, 303-310.	1.5	0
141	Giant Cell Arteritis: Navigating Beyond the Headache. EMJ Radiology, 0, , .	0.0	0
142	AB0674â€¦...RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY. Annals of the Rheumatic Diseases, 2021, 80, 1368.3-1369.	0.9	0
143	POS0051â€¦...THE IMPACT OF COVID-19 ON RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY. Annals of the Rheumatic Diseases, 2021, 80, 230.2-231.	0.9	0
144	AB0404â€¦...EXTENDED MYOSITIS PANEL AND THE CLINICAL ASSOCIATION IN PATIENT WITH SUSPECTED INFLAMMATORY DISEASE, A RETROSPECTIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1230.2-1231.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Is troponin testing rather underestimated in clinic practice? Evidence from emergency medical admissions: Authors response. European Journal of Internal Medicine, 2021, 90, 106.	2.2	0
146	Comment to: Non-specific clinical presentations are not prognostic and do not anticipate hospital length of stay or resource utilization: Author's reply. European Journal of Internal Medicine, 2021, 91, 87.	2.2	0
147	SAT0087â€¦Association of biometrics with disease characteristics and synovial phenotype in inflammatory arthritis. , 2018, , .		0
148	SAT0542â€¦Interleukin-12 and interleukin-23 are key pathogenic players in giant cell arteritis. , 2018, , .		0
149	The Problems with Risk Prediction during an Emergency Medical Admission Using Laboratory Data â€“ Evidence from Potassium. Acute Medicine, 2019, 18, 16-22.	0.3	0
150	Socio-Economic Status and MultiOriginal morbidity â€“ Fact or Fiction?. Acute Medicine, 2019, 18, 64-70.	0.3	0
151	Air pollution and age: Do older persons suffer more?. Environmental Disease, 2020, 5, 44.	0.1	0
152	Troponin status predicts 30-day in-hospital mortality. Vessel Plus, 0, 2020, .	0.4	0
153	Limited Prognostic Utility of a Simplified Vital Sign Based Risk Calculator in Acute Medical Admissions. Acute Medicine, 2020, 19, 138-144.	0.3	0
154	Dr. Conway et al reply. Journal of Rheumatology, 2022, 49, 120.2-121.	2.0	0
155	Where do we go after GIACTA?. Rheumatology, 2022, , .	1.9	0
156	A case of occupational gout. Irish Medical Journal, 2011, 104, 316-7.	0.0	0
157	Ireland's recent contribution to the radiological literature; a bibliometric analysis. Irish Medical Journal, 2017, 110, 544.	0.0	0
158	Socio-Economic Status and MultiOriginal morbidity - Fact or Fiction?. Acute Medicine, 2019, 18, 64-70.	0.3	0
159	The Problems with Risk Prediction during an Emergency Medical Admission Using Laboratory Data - Evidence from Potassium. Acute Medicine, 2019, 18, 20-26.	0.3	0
160	Limited Prognostic Utility of a Simplified Vital Sign Based Risk Calculator in Acute Medical Admissions. Acute Medicine, 2020, 19, 138-144.	0.3	0
161	Efficacy and Safety of Conventional Synthetic, Biologic and Targeted Synthetic DMARDs in RA-ILD: A Narrative Review. Indian Journal of Rheumatology, 2023, 18, 303-311.	0.4	0
162	Hospital mortality and length of stay differences in emergency medical admissions related to â€“on-callâ€™ specialty. Irish Journal of Medical Science, 0, , .	1.5	0